NEW YORK (GenomeWeb) – Labcyte and Notable Labs said today that they have inked an agreement under which Notable Labs will use Labcyte's Echo acoustic liquid handling technology for personalizing drug therapy.

Notable, a clinical oncology company, will employ the Echo technology in its fully automated, high-throughput laboratory to functionally assess the effects of FDA-approved drugs on live primary cancer cells from individual patients, the companies said.

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.